Physician profile
Robert M Wheeler
NPI 1902897846
$2,007.56
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $480 · 2021: $897 · 2022: $300.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.94 | 2021-2022 | |
| Novo Nordisk INC | $206.00 | 2019-2022 | |
| Amgen INC. | $150.61 | 2019-2022 | |
| Allergan, INC. | $134.51 | 2020 | |
| Amneal Pharmaceuticals LLC | $116.78 | 2021-2022 | |
| Glaxosmithkline, LLC. | $112.48 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $107.32 | 2021 | |
| Esperion Therapeutics, INC. | $91.78 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $83.08 | 2019-2022 | |
| Lilly USA, LLC | $79.00 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.12 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $73.34 | 2020-2022 | |
| Sanofi Pasteur INC. | $63.02 | 2019-2020 | |
| Pfizer INC. | $56.84 | 2020-2021 | |
| Amarin Pharma, INC. | $55.65 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $52.32 | 2021 | |
| Abbott Laboratories | $34.25 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.76 | 2020 | |
| Melinta Therapeutics, LLC | $16.60 | 2019 | |
| Medtronic Vascular, INC. | $15.76 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.37 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.15 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.81 | 2020 | |
| Genentech USA, INC. | $12.80 | 2020 | |
| Shire North American Group INC | $12.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.